Although this decision is unlikely to have a significant impact on Pravachol sales, it's still disappointing for BMS. It needs any revenue boost it can get this year, as sales of many of its other blockbuster drugs plummet. The FDA decision may also affect other players that plan to market single pills containing compounds for different indications, including Pfizer.
The Fijian government has declared a 4,400% taxation increase on water extracted from the country, which has resulted in the probable closure of Fiji Water's only bottling plant. As the company's marketing message relies upon its location in the South Pacific, it is difficult to see any future for the brand unless a compromise can be reached.
Edit my basket
© Datamonitor 2014. All rights reserved
Terms & Conditions